Ibandronate — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Osteoporosis

• Alendronate
• Raloxifene
• Risedronate

Other medications in Musculoskeletal

• Indomethacin
• Meloxicam
• Naproxen
• Acetaminophen
• Allopurinol
• Celecoxib
• Colchicine
• Diclofenac

About Ibandronate

Ibandronate is a vital medication prescribed to help strengthen bones and prevent fractures, especially for women after menopause. Managing chronic conditions can be costly, but with TheDrugClub, members can access essential medications like ibandronate with significant savings, often for a $0 co-pay and free home delivery, making bone health more accessible.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ibandronate is approved for (FDA label)

Ibandronate Sodium Tablets are a bisphosphonate indicated for the treatment and prevention of post-menopausal osteoporosis. (1.1) Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.2). 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate Sodium Tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium increases bone mineral density (BMD) and reduces the incidence of vertebral fractures. 1.2 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiveness of Ibandronate Sodium Tablets for the treatment of osteoporosis are based on clinical data of three years duration.

Source: Read the full FDA label on DailyMed. Label effective date: August 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ibandronate (FDA label)

Ibandronate Sodium Tablets 150 mg (ibandronate): yellow colored capsule shaped film-coated tablets debossed with “ID” on one side and “150” on the other side. Tablets: 150 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985. SPL document ID: 55845f3d-9d8b-4426-96ea-e73438e380d1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ibandronate (FDA label)

The following clinically significant adverse drug reactions are described elsewhere in the labeling: • Upper Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1)] • Hypocalcemia and Mineral Metabolism [see Warnings and Precautions (5.2)] • Musculoskeletal [see Warnings and Precautions (5.3)] • Jaw Osteonecrosis [see Warnings and Precautions (5.4)] • Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5)] • Severe Renal Impairment [see Warnings and Precautions (5.6)] The most common adverse reactions (greater than 5%) are back pain, dyspepsia, pain in extremity, diarrhea, headache, and myalgia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-BION or 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985. SPL document ID: 55845f3d-9d8b-4426-96ea-e73438e380d1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ibandronate (FDA label)

Ibandronate sodium is contraindicated in patients with the following conditions: • Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see Warnings and Precautions [ 5.1 ]) • Inability to stand or sit upright for at least 60 minutes (see Dosage and Administration [2.2], and Warnings and Precautions [ 5.1 ]) • Hypocalcemia (see Warnings and Precautions [ 5.2 ]) • Known hypersensitivity to ibandronate sodium tablets or to any of its excipients. Cases of anaphylaxis have been reported. (see Adverse Reactions [6.2]) . • Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 , 5.1 ) • Inability to stand or sit upright for at least 60 minutes ( 4 , 5.1 ) • Hypocalcemia ( 4 ) • Hypersensitivity to ibandronate sodium ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985. SPL document ID: 55845f3d-9d8b-4426-96ea-e73438e380d1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ibandronate (FDA label)

Upper gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions and discontinue use if new or worsening symptoms occur. ( 5.1 ) Hypocalcemia may worsen during treatment. Correct hypocalcemia before use. ( 5.2 ) Severe Bone, Joint, and Muscle Pain may occur. Consider discontinuing use if symptoms develop. ( 5.3 ) Osteonecrosis of the Jaw has been reported. ( 5.4 ) Atypical Fractures Including Femoral Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered (5.5) 5.1 Upper Gastrointestinal Adverse Reactions Ibandronate sodium, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa.

Source: FDA prescribing information (DailyMed). Set ID: 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985. SPL document ID: 55845f3d-9d8b-4426-96ea-e73438e380d1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ibandronate (FDA label)

• Calcium supplements, antacids and some oral medications may interfere with absorption of ibandronate. Do not take within 60 minutes of dosing ( 7.1 ) • Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7.2 ) 7.1 Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of ibandronate sodium. Therefore, instruct patients to take ibandronate sodium at least 60 minutes before any oral medications, including medications containing multivalent cations (such as antacids, supplements or vitamins).

Source: FDA prescribing information (DailyMed). Set ID: 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985. SPL document ID: 55845f3d-9d8b-4426-96ea-e73438e380d1. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.